In one of the first in-human studies to investigate whether modifying the gut microbiome by a fecal microbiota transplant could make cancer immunotherapy more effective, researchers analyzing this in ten cancer patients with refractory melanoma suggest the treatment can improve patient outcomes. Their results - which show a positive response in three out of the ten patients analyzed - are reported from a Phase 1 clinical trial.
Though noting some limitations of their work, the authors say their findings support the concept of overcoming resistance to immunotherapy by modulating the gut microbiota.
Many cancer patients who receive PD-1 blockade therapy do not respond to it, developing resistance. Among the most promising routes for overcoming resistance to anti-PD-1 therapy is altering the gut microbiome, which has been shown to influence the response of tumors to anti-PD-1 immunotherapy in pre-clinical mouse models and observational patient cohorts.
While no specific bacterial taxa have been consistently associated with this response, fecal microbiota transplantation (FMT) - which transfers the entire gut microbiota from one host to another - has demonstrated promising results in pre-clinical models.
Based on this data, the authors designed a Phase 1 clinical test to evaluate how FMT, followed by re-initiation of anti-PD-1 immunotherapy, affected ten patients with metastatic melanoma who'd previously grown resistant to anti-PD-1 treatment. The transplant material was from one of two melanoma patients ("Donor 1" or "Donor 2"), both of whom had responded positively to anti-PD-1 therapy for at least one year.
After receiving FMT from Donor 1 or Donor 2, three out of ten patients responded to subsequent anti-PD-1 treatment, as defined by regression of tumor size. All three had received their FMT from Donor 1, the authors note. The reason for the positive response as derived from Donor 1 alone is not clear, they say, as the study was statistically powered to assess safety and not to compare efficiency between donors.
Even as the results offer no clear association between specific taxa and clinical response to FMT, however, they point to the combination of FMT and re-induction of anti-PD-1 therapy being "safe, feasible and potentially effective," say the authors.
https://science.sciencemag.org/content/early/2020/12/09/science.abb5920
Fecal microbiota transplant impacts cancer patients resistant to immunotherapy
- 1,361 views
- Added
Edited
Latest News
Protease action on controll…
By newseditor
Posted 25 May
Maternal inflammation activ…
By newseditor
Posted 25 May
How cells deal with extra c…
By newseditor
Posted 25 May
Flicker stimulation modulat…
By newseditor
Posted 25 May
Multi-dose TB vaccines prot…
By newseditor
Posted 24 May
Other Top Stories
New method to target rheumatoid arthritis
Read more
Treating children with cerebral palsy
Read more
How different brain regions are connected
Read more
Treating epilepsy with a new on-demand and cell-autonomous gene the…
Read more
Mapping the path from smell to perception
Read more
Protocols
Spatially resolved lipidomi…
By newseditor
Posted 24 May
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Publications
Cryo-EM reveals that iRhom2…
By newseditor
Posted 25 May
Fetal brain response to mat…
By newseditor
Posted 25 May
Children born after assiste…
By newseditor
Posted 25 May
Macrophage-induced integrin…
By newseditor
Posted 25 May
Copy number alterations: a…
By newseditor
Posted 25 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar